equillium
announces
positive
interim
data
itolizumab
treatment
acute
disease
overall
response
rate
dose
cohort
overall
response
rate
across
cohorts
date
complete
response
observed
seven
eight
responding
patients
equate
phase
topline
data
expected
first
half
la
jolla
globe
newswire
equillium
nasdaq
eq
biotechnology
company
developing
itolizumab
treat
severe
autoimmune
inflammatory
disorders
today
announced
positive
interim
data
third
cohort
phase
open
label
dose
escalation
study
itolizumab
treatment
acute
disease
agvhd
equate
trial
evaluating
itolizumab
severe
agvhd
patients
concomitant
standard
care
typically
comprised
high
dose
corticosteroids
therapeutics
currently
approved
indication
equillium
anticipates
reporting
topline
data
across
cohorts
phase
portion
equate
trial
first
half
accelerating
plans
development
itolizumab
disease
equate
trial
overall
response
rate
across
first
three
dose
cohorts
seven
eight
patients
responding
achieved
complete
response
cr
one
patient
achieved
good
partial
response
vgpr
day
vgpr
approximates
clinical
benefit
cr
responses
observed
rapid
patients
achieving
cr
within
first
days
durable
patients
first
two
cohorts
maintained
responses
day
date
adverse
events
reported
equate
trial
consistent
safety
profile
previously
reported
itolizumab
common
agvhd
patient
population
review
totality
safety
efficacy
pharmacodynamic
data
independent
data
monitoring
committee
recommended
expand
cohort
mg
kg
dose
proceed
forward
enrollment
continue
accrue
compelling
data
equate
trial
rapid
durable
response
rates
patients
treated
itolizumab
meaningfully
exceeds
observed
patients
severe
agvhd
treated
steroids
alone
said
bruce
steel
chief
executive
officer
equillium
plan
engage
food
drug
administration
fda
explore
expedited
regulatory
pathways
advance
itolizumab
treatment
agvhd
data
suggests
opportunities
expand
potential
therapeutic
application
itolizumab
patients
chronic
gvhd
potential
preventative
treatment
patients
undergone
hematopoietic
stem
cell
transplantation
believe
itolizumab
potential
medicine
agvhd
patients
severe
illness
currently
approved
equate
study
results
itolizumab
response
rates
day
agvhd
cohort
itolizumab
dose
mg
kg
number
patients
number
cr
vgpr
pr
cr
vgpr
rate
number
response
overall
response
rate
total
complete
response
cr
good
partial
response
vgpr
approximates
clinical
benefit
complete
response
partial
response
pr
equillium
received
fast
track
designation
fda
treatment
itolizumab
patients
agvhd
orphan
drug
designations
fda
prevention
treatment
agvhd
equillium
plans
provide
additional
updates
program
upcoming
analyst
day
december
disease
gvhd
multisystem
disorder
common
complication
allogeneic
hematopoietic
stem
cell
transplants
caused
transplanted
immune
system
recognizing
attacking
recipient
body
symptoms
gvhd
include
rash
itching
skin
discoloration
nausea
vomiting
diarrhea
jaundice
well
eye
dryness
irritation
gvhd
leading
cause
mortality
cancer
patients
receiving
risk
gvhd
limits
number
type
patients
receiving
hsct
gvhd
results
high
morbidity
mortality
survival
approximately
patients
respond
steroid
treatment
mortality
high
patients
respond
steroids
agvhd
setting
published
literature
macmillan
et
describes
background
response
rates
steroid
administration
less
severe
standard
risk
patients
overall
response
rate
orr
cr
whereas
severe
patients
response
rates
observed
orr
cr
equate
study
equate
study
phase
trial
evaluate
safety
tolerability
pharmacokinetics
pharmacodynamics
clinical
activity
itolizumab
treatment
patients
present
agvhd
nct
phase
part
trial
dose
escalation
study
adult
patients
present
severe
agvhd
grades
iii
iv
typically
respond
poorly
steroids
phase
data
inform
selection
dose
used
next
phase
development
program
itolizumab
itolizumab
monoclonal
antibody
selectively
targets
pathway
pathway
plays
central
role
modulating
activity
trafficking
cells
drive
number
diseases
itolizumab
currently
evaluated
multiple
clinical
trials
patients
severe
diseases
including
agvhd
lupus
nephritis
uncontrolled
asthma
soon
evaluated
clinical
trial
patients
equillium
acquired
rights
itolizumab
exclusive
partnership
biocon
limited
itolizumab
marketed
india
trade
name
treatment
chronic
plaque
psoriasis
received
emergency
use
approval
india
treat
cytokine
release
syndrome
patients
moderate
severe
acute
respiratory
distress
syndrome
equillium
equillium
biotechnology
company
leveraging
deep
understanding
immunobiology
develop
novel
products
treat
severe
autoimmune
inflammatory
disorders
high
unmet
medical
need
equillium
developing
itolizumab
multiple
severe
diseases
including
agvhd
lupus
nephritis
uncontrolled
asthma
information
visit
forward
looking
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
statements
include
limited
potential
benefit
treating
agvhd
chronic
gvhd
patients
well
patients
undergone
hematopoietic
stem
cell
transplantation
itolizumab
equillium
business
strategy
equillium
plans
expected
timing
developing
itolizumab
including
expected
timing
completion
equate
study
initiating
clinical
trial
patients
potential
interim
data
results
consistent
final
results
available
potential
benefits
itolizumab
potential
equillium
ongoing
planned
clinical
trials
show
safety
efficacy
impact
pandemic
risks
contribute
uncertain
nature
statements
include
risk
interim
results
clinical
trial
necessarily
predict
final
results
one
clinical
outcomes
may
materially
change
patient
enrollment
continues
following
comprehensive
reviews
data
patient
data
become
available
potential
delays
commencement
enrollment
completion
clinical
trials
reporting
data
therefrom
risk
studies
completed
planned
uncertainties
related
equillium
capital
requirements
equillium
plans
product
development
including
initiation
restarting
completion
clinical
trials
uncertainties
related
actual
impacts
length
impacts
caused
pandemic
uncertainties
caused
recent
restarting
equip
equalise
clinical
trials
pause
whether
results
clinical
trials
validate
support
safety
efficacy
itolizumab
use
cash
ways
timing
expected
impact
market
volatility
cash
reserves
risks
uncertainties
described
fully
caption
risk
factors
elsewhere
equillium
filings
reports
united
states
securities
exchange
commission
statements
contained
press
release
speak
date
made
equillium
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
investor
contact
christine
zedelmayer
chief
operating
officer
ir
media
contact
katherine
carlyle
smith
senior
account
associate
canale
communications
